“Global Competent Cells Market to reach a market value of USD 3.7 Billion by 2031 growing at a CAGR of 7.9%”
The Global Competent Cells Market size is expected to reach $3.7 billion by 2031, rising at a market growth of 7.9% CAGR during the forecast period.
Rising healthcare expenditures in Asia Pacific countries fuel demand for innovative biopharmaceuticals, personalized medicine, and diagnostic tools. These cells are essential in developing these healthcare solutions, contributing to market growth. Consequently, the Asia Pacific region would acquire nearly 30% of the total market share by 2031.
Recombinant DNA technology is fundamental for cloning and expressing genes in host cells. These cells are essential for introducing recombinant DNA into bacterial cells to produce therapeutic proteins, enzymes, and vaccines. In addition, the development of personalized medicine, which tailors’ treatments based on individual genetic profiles, relies on recombinant DNA technology and these cells. Hence, the growing demand for recombinant DNA technology drives the market's growth.
Additionally, these cells are essential for introducing and expressing genes of interest to study their functions. Researchers use these cells to clone specific genes, manipulate DNA sequences, and explore gene interactions, which are fundamental in understanding biological processes and disease mechanisms. Thus, the expansion of genomic and proteomic studies is propelling the market's growth.
Moreover, the pandemic spurred heightened demand for these cells as pharmaceutical and biotech companies accelerated research and development efforts for vaccines and therapies. Also, companies in the competent cells sector adapted quickly to ensure uninterrupted supply chains, enhancing market stability and growth during the pandemic. Thus, the COVID-19 pandemic had a positive impact on the market.
However, establishing a competent cell production facility requires significant investment in specialized equipment such as bioreactors, incubators, purification systems, and sterile facilities. Moreover, scaling up production from laboratory-scale to commercial quantities can involve additional costs related to process optimization, validation, and facility expansion. Hence, high initial costs are hindering the growth of the market.
Based on type, the market is divided into chemically competent cells, electrocompetent cells, and ultracompetent cells. The electrocompetent cells segment attained 34% revenue share in the market in 2023. Electrocompetent cells typically offer higher transformation efficiencies compared to chemically competent cells. This makes them suitable for applications that require precise control over transformation efficiency, such as gene editing, library construction, and high-throughput screening.
On the basis of application, the market is segmented into cloning, protein expression, mutagenesis, and others. In 2023, the protein expression segment attained a 24% revenue share in the market. These cells with high transformation efficiencies and robust protein expression capabilities are preferred for generating large quantities of recombinant proteins.
By end-use, the market is divided into pharmaceutical & biotechnology companies, academic & research institutes, and others. The academic & research institutes segment procured a 37% revenue share in the market in 2023. These cells are fundamental tools in molecular biology research for studying gene function, protein expression, and genetic pathways. Academic institutions use these cells to conduct basic research that advances our understanding of biological processes and diseases.
Free Valuable Insights: Global Competent Cells Market size to reach USD 3.7 Billion by 2031
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed 35% revenue share in the market in 2023. North America hosts some of the world’s leading biotechnology and pharmaceutical companies, particularly the United States and Canada. These industries drive substantial demand for these cells for research, development, and production of biopharmaceuticals, vaccines, and therapeutic proteins.
| Report Attribute | Details |
|---|---|
| Market size value in 2023 | USD 2.0 Billion |
| Market size forecast in 2031 | USD 3.7 Billion |
| Base Year | 2023 |
| Historical Period | 2020 to 2022 |
| Forecast Period | 2024 to 2031 |
| Revenue Growth Rate | CAGR of 7.9% from 2024 to 2031 |
| Number of Pages | 237 |
| Tables | 360 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives |
| Segments covered | Type, Application, End-Use, Region |
| Country scope |
|
| Companies Included | Thermo Fisher Scientific, Inc., Merck KGaA, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Promega Corporation, New England Biolabs, Inc., Qiagen N.V, F. Hoffmann-La Roche Ltd., Takara Bio Inc. (Takara Holdings Inc.) and Lonza Group Ltd. (Capsugel) |
By Type
By Application
By End-Use
By Geography
This Market size is expected to reach $3.7 billion by 2031.
Growing demand for recombinant DNA technology are driving the Market in coming years, however, High initial costs restraints the growth of the Market.
Thermo Fisher Scientific, Inc., Merck KGaA, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Promega Corporation, New England Biolabs, Inc., Qiagen N.V, F. Hoffmann-La Roche Ltd., Takara Bio Inc. (Takara Holdings Inc.) and Lonza Group Ltd. (Capsugel)
The expected CAGR of this Market is 7.9% from 2024 to 2031.
The Cloning segment led the Market by Application in 2023; thereby, achieving a market value of $1.5 billion by 2031.
The North America region dominated the Market by Region in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $1.3 billion by 2031.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 